A Prospective, Multi-center, Open-label, Pivotal Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Stimulation in Advanced Levodopa-Responsive Parkinson's Disease Treated With Bilateral Deep Brain Stimulation
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 主要终点
- To assess Treatment-Emergent Adverse Events
研究概览
简要总结
The clinical trial aims to evaluate the safety and effectiveness of bilateral subthalamic nucleus (STN) and Globus Pallidus internus (GPi) deep brain stimulation (DBS) with the AlphaDBS IPG System when programmed in adaptive versus conventional stimulating modes. It includes an initial open-label, crossover phase and a long term follow-up phase, during which the patient is free to switch between stimulating modes.
详细描述
This is an international multi-center (North America and Europe) clinical trial to evaluate the safety and effectiveness of bilateral STN and GPi DBS with the AlphaDBS IPG System when programmed in adaptive (aDBS) versus conventional (cDBS) stimulating modes, in patients with advanced levodopa-responsive Parkinson's disease (PD).
The protocol is comprised of:
Phase 1: Initial Treatment Period: Cross-Over Design
- Phase 1a: All patients will start the study in cDBS mode. After a 1-month post-surgical stabilization, the AlphaDBS IPG System will be turned ON in cDBS mode. Participants will complete a 1-month period of programming optimization (to fine tune medical therapies and stimulation parameters) followed by a 3-month period of cDBS.
- Phase 1b: At the end of the 3-month follow up in cDBS, participants will be switched to the aDBS mode. Participants will then complete a 1-month period of optimization (to fine tune medical therapies and stimulation parameters) followed by a 3-month period of aDBS.
Phase 2: Long-term follow-up: Naturalistic Follow-up Design Patients completing Phase 1 are eligible to enter long-term follow-up for up to an additional 28 months. During this time, patients are free to change the DBS mode as preferred (with a maximum switches set by the physician). Visits at 6-month follow-ups will collect safety and efficacy data.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 95 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥55 years old
- •Patient has been diagnosed with levodopa-responsive idiopathic Parkinson's disease for ≥5 years
- •The disease stage is II, III or IV according to the Hoehn and Yahr scale
- •Patient has history of improvement of Parkinson's symptoms as a direct result of administering levodopa
- •PD-related symptoms are not adequately controlled with medication, including motor complications of recent onset (>4 months duration)
- •Patient experiences persistent disabling PD-related symptoms or drug side effects (e.g., dyskinesia, motor fluctuations, or disabling "off periods") despite optimal medical therapy
- •Patient has been selected for bilateral STN or Gpi DBS, independently from this study, in accordance with local standard of care DBS screening
- •Patient has been selected to receive Medtronic leads model 3389 or 37086, independently from this study, in accordance with local standard of care DBS screening
- •Patient has DBS circuit integrity assessed and confirmed by impedance testing, before IPG implantation
- •≥6 hours per day (waking hours) with poor motor symptoms control (time "OFF" plus time "ON" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary
- •Montreal Cognitive Assessment (MoCA) >26 in MedON condition
- •Beck Depression Inventory II (BDI-II) score <17 in MedON condition
- •UPDRS-III improvement by ≥33% following intake of anti-parkinsonian medications
- •Patient is able to understand the study requirements and the treatment procedures and has provided written informed consent to participate
- •Patient is willing and capable of completing a 3-day diary and reaches a sufficient level of agreement (> 75%) with study personnel responses
- •Patient has a responsible caregiver who will help completing the 3-day diary, provide feedback on activities of daily living (ADL), and ensure the patient complies with visit schedule
- •Patient is willing to maintain a constant anti-PD medication treatment (best medical management) for at least one month prior to study enrollment
- •Patient is willing and able to attend all study-required visits, complete the study procedures and attend appropriate follow up visits
排除标准
- •Patient has contraindications for DBS surgery, including any intracranial abnormality (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant (e.g., aneurysm clip, cochlear implant, etc.)
- •Patient has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Item 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSR-S)
- •Patient has dementia, major depression, seizures, congestive heart failure, uncontrolled diabetes, dialysis, substance use disorders as described in DSM-V, or any other severe medical condition
- •Patient has any medical condition that could interfere with study procedures, confound the assessment of study endpoints, or prevent a proper data collection
- •Patient had confirmation of diagnosis of a terminal illness associated with survival <12 months
- •Patient needs repeated MRI scans
- •Patient requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
- •Patient carries an electrical or electromagnetic implant (e.g., cochlear prosthesis, pacemaker, neurostimulator, etc.)
- •Patient has, or plans to obtain, an implanted electrical stimulation medical device and/or an implanted medication pump (e.g., DUOPATM infusion pump) and/or is treated with a portable infusion pump
- •Patient is on anticoagulant therapy which cannot be paused for >5 days before IPG implant surgery
- •Patient with a history of cranial surgery including ablation procedure or any other previous neurosurgical procedure for the treatment of PD symptoms on either side of the brain
- •Patient is currently participating in another clinical study (excluding any sub-study of the present study)
- •Patient is a female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.
结局指标
主要结局
To assess Treatment-Emergent Adverse Events
时间窗: 9 months
To identify Treatment-Emergent Adverse Events (TEAEs) (including serious, device-related, stimulation-related, and/or procedure related TEAEs), discontinuations of aDBS and study discontinuation and physical or neurological findings as categorized by the Data and Safety Monitoring Board.
To compare change in Good on time (GOT) when the patient receives aDBS versus change in GOT when the patient receives cDBS.
时间窗: 9 months
The expected treatment effectiveness of AlphaDBS IPG System with aDBS mode (∆GOTaDBS = GOTaDBS@3-Months - GOT@Baseline) and with cDBS mode (∆GOTcDBS = GOTcDBS@3-Months - GOT@Baseline) will not differ more than two hours.
次要结局
- Success rate, number of patients with at least 2 hours improvement in each treatment mode(9 months)
- Percentage of time in which the system is used in aDBS mode(28 months)
- Patient fluctuations(9 months and 36 months)
- UPDRS III(9 months and 36 months)
- UdysRS(9 months and 36 months)